feed,title,long_url,short_url
Benzinga,C4 Therapeutics Doses First Patient in Phase 1/2 Trial of CFT8634 For SMARCB1-perturbed cancers,https://benzinga.com/general/biotech/22/05/27226746/c4-therapeutics-doses-first-patient-in-phase-12-trial-of-cft8634-for-smarcb1-perturbed-cancers,https://bit.ly/37SdZVG
